April was one of the worst months in the history of Cochlear Ltd (ASX: COH).
Cochlear shares crashed 41% in a single session on 22 April after the company delivered one of the most severe earnings downgrades in its listed history.
In May however, Cochlear shares were able to stage a modest comeback.
Here's what happened.
Image source: Getty Images
Cochlear shares recovered approximately 7% in May
From that decade low of $90, Cochlear shares bounced to $100.50 by the end of May.
That represents a recovery of approximately 12% from the April lows.
However, Cochlear shares remain down 61.50% year to date and down approximately 63% in the last twelve months.
The May recovery reflects a combination of bargain hunting from long-term investors and growing broker interest at the lower price level.
Indeed, Cochlear shares were starting to look more interesting after the market had already punished the stock heavily for the downgrade.
What drove the recovery in Cochlear shares
Three factors supported the partial recovery during May.
First, the broader healthcare sector stabilised somewhat after the brutal April rotation out of defensive stocks.
Second, broker commentary grew more constructive.
Jarden and Wilsons Advisory both see upside of more than 100% in COH shares over the next twelve months.
Third, CEO Dig Howitt continued to make the case that the volume weakness is temporary rather than permanent.
He said:
The clinical need for cochlear implants continues to grow, particularly for the adult and seniors segment. Cochlear implants are also associated with a lower incidence of dementia, with dementia rates lower than in hearing aid users and comparable to those with normal hearing.
The risks that remain
Nevertheless, Cochlear shares shares face near-term challenges.
Hospital capacity constraints and reduced referral activity from the hearing aid channel in the US and Europe have not yet resolved.
The $25 million after-tax foreign exchange headwind remains in place.
Middle East receivables continue to create uncertainty.
Moreover, the FY2026 earnings downgrade has shaken investor confidence in a way that typically takes several consecutive quarters of stable results to rebuild.
Morgans retained a hold rating but cut its price target in half to $107.17 from $214.93, stating:
COH has delivered a material downgrade to FY26 earnings, cutting guidance by c30% at the midpoint. This demonstrates that cochlear implant demand is more cyclical and macro-sensitive than previously assumed.
Meanwhile, Macquarie slashed its price target from $239 to $115, reflecting its view that the near-term earnings recovery will take longer than the market had anticipated.
Foolish takeaway
Cochlear shares bounced approximately 7% in May after touching decade lows.
That recovery is encouraging but tentative.
The fundamental demand picture for cochlear implants has not changed.
Cochlear still holds approximately 50% global market share in a market with just 3% penetration of an addressable patient population exceeding six million people in developed markets alone.
For patient investors with a multi-year time horizon, May may prove to have been an interesting entry point for Cochlear shares.
